BioSpace News Archive

Q1 2019 net income of $0.64 per basic and $0.62 per diluted share and adjusted non-GAAP net income of $1.05 per basic and $1.01 per diluted share

Premier value-based healthcare technology company joins health plan association to assist in empowering healthcare in the state of Florida

Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST

Intec Pharma Ltd. announces financial results for the three months ended March 31, 2019 and provides a corporate update.

Oral plenary presentation to detail properties of oral, gut-restricted alpha-4-beta-7 integrin antagonist candidate PN-943

The Medicines Company announced that it will participate in the Bank of America Merrill Lynch 2019 Healthcare Conference on Tuesday, May 14, 2019, in Las Vegas.

Also presented were results from a meta-analysis of DecisionDx-Melanoma in 1,479 patients which provides the highest level of evidence (1A) as an independent, significant predictor of risk in cutaneous melanoma

Charles River Laboratories International, Inc. reported its results for the first quarter of 2019.

Open-label, long-term extension data show durability of zilucoplan treatment effect, with sustained improvements observed in primary and secondary endpoints at 24 weeks

Pfizer Inc. announced that the European Commission granted conditional marketing authorization for LORVIQUA®, as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor therapy, or crizotinib and at least one other ALK TKI.